Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupHead and Neck OncologyradiotherapyDiseaseSalivary Gland TumorSubgroupICD10C08.-MeSHSalivary Gland NeoplasmsSequenceChemotherapyChemo-substanceCisplatinChemo-substanceCisplatinChemo-substanceCisplatinChemo-substanceCisplatinNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideNo. Substances6Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO)HeadacheMucositisRash only studiesPublicationAuthorBhattasali ODiseaseSpeicheldrüsentumor, lokal fortgeschritten, nach oder ohne Debulking-OPOriginDepartment of Radiation Oncology, Kaiser Permanente Medical Center, Los Angeles, CaliforniaProtocols in Revision 1 protocol foundProtocols under revision.Cisplatin 40 / Radiation, Salivary Gland Tumor (PID1699 V1.1)
